Researchers are targeting epigenetic resistance mechanisms in EGFR-mutant lung cancer. A preclinical study reports that decitabine restored sensitivity to osimertinib in resistant non-small cell lung cancer models, pointing to TP53INP1 as a candidate mediator and implicating autophagy-linked pathways. The work used methylation profiling alongside gene expression analyses to connect promoter methylation changes to drug-response restoration, offering a rationale for combination strategies in hard-to-treat EGFR resistance states.